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Purpose: Unexpected requests for non-cardiac surgery requiring discontinuation 
of dual antiplatelet therapy (DAPT) frequently occur in daily clinical practice. 
The objectives of this study were to evaluate prevalence, timing and clinical out-
comes of such unexpected requests for non-cardiac surgery or other invasive pro-
cedures during the first year after drug-eluting stents (DESs) implantation. Mate-
rials and Methods: We prospectively investigated the prevalence, timing and 
clinical outcomes of unexpected requests for non-cardiac surgery or other proce-
dures during the first year after DESs implantation in 2117 patients. Results: The 
prevalence of requested non-cardiac surgery or invasive procedures was 14.6% in 
310 requests and 12.3% in 261 patients. Among 310 requests, those were pro-
posed in 11.3% <1 month, 30.0% between 1 and 3 months, 36.8% between 4 and 
6 months and 21.9% between 7 and 12 months post-DES implantation. The rates 
of actual discontinuation of DAPT and non-cardiac surgery or procedure finally 
performed were 35.8% (111 of 310 requests) and 53.2% (165 of 310 requests), 
respectively. On multivariate regression analysis, the most significant determi-
nants for actual discontinuation of DAPT were Endeavor zotarolimus-eluting 
stent implantation with 3-month DAPT (OR=5.54, 95% CI 2.95-10.44, p<0.001) 
and timing of request (OR=2.84, 95% CI 1.97-4.11, p<0.001). There were no pa-
tients with any death, myocardial infarction, or stent thrombosis related with ac-
tual discontinuation of DAPT. Conclusion: Those unexpected requests with pre-
mature discontinuation of DAPT were relatively common and continuously 
proposed during the first year following DES implantation. No death, myocardial 
infarction or stent thrombosis occurred in patients with actual discontinuation of 
DAPT.
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the current guideline regarding the management of the pa-
tients treated with DES.6 In addition, for patients who un-
derwent surgery or procedures that required mandatory dis-
continuation of antiplatelet therapy, aspirin was continued if 
possible at all.6,7 In the case of high-risk patients who had to 
undergo surgery or procedures after complete discontinua-
tion of DAPT, early hospital admission for monitoring and 
surveillance was strongly recommended. All study partici-
pants provided written informed consent using documents 
approved by the institutional review board at each partici-
pating center.
 
Follow-up and definitions
Details regarding unexpected requests from various health 
providers requiring discontinuation of DAPT in order to 
perform non-cardiac surgery or other invasive procedures 
during the first 12 months post-DES implantation were col-
lected using a questionnaire completed by physicians who 
performed the DES implantation procedures. This ques-
tionnaire included 1) reasons for discontinuation of DAPT, 
2) exact non-cardiac surgery or invasive procedures that 
were requested, 3) whether DAPT was actually discontin-
ued, 4) whether the surgical or invasive procedures were 
performed or deferred, and 5) clinical outcomes of the pa-
tients. Discontinuation of DAPT was defined as the discon-
tinuation of any antiplatelet agents in a patient being treated 
with more than one agent or discontinuation of aspirin in 
case of aspirin mono-therapy. Surgery or procedures were 
classified into six categories based on the previous and the 
current guidelines considering the characteristics of proce-
dures: 1) high-risk operation (aortic, peripheral vascular, or 
emergent operation); 2) intermediate-risk operation (intra-
peritoneal and intrathoracic surgery, carotid endarterecto-
my, head and neck surgery, orthopedic surgery, or prostate 
surgery); 3) low-risk operation (cataract, breast surgery, or 
ambulatory surgery); 4) invasive diagnostic or therapeutic 
procedures, defined as procedures performed under the 
guidance of fluoroscopy without general anesthesia; 5) den-
tal operation or procedures; and 6) endoscopic operations or 
procedures without general anesthesia.7,9 For surveillance re-
garding the duration, use, or discontinuation of DAPT, we 
used the Korean national healthcare monitoring system that 
tracks the use of specific drugs in Korea including direct re-
view of patient medical records, phone visits, and personal 
e-mail contacts. In case of discontinuation of DAPT for un-
expected operations or other invasive procedures, the tests 
of electrocardiogram or cardiac enzymes including early 
INTRODUCTION
Although early discontinuation of clopidogrel has been re-
garded as a strong predictor for the occurrence of stent 
thrombosis following drug-eluting stent (DES) implanta-
tion, unexpected minor and major operations or other inva-
sive procedures requiring discontinuation of dual antiplate-
let therapy (DAPT) frequently occur in real world daily 
clinical practice.1-5 Therefore, many advisory groups recom-
mend postponing elective surgery.6,7 However, to date, data 
on prevalence, timing, and clinical outcomes of unexpected 
requests for non-cardiac surgery or other invasive proce-
dures after DES implantation are scarce. Therefore, we 
used the data from the randomized REal Safety and Effica-
cy of 3-month dual antiplatelet Therapy following Endeav-
or zotarolimus-eluting stent implantation (RESET) trial to 
prospectively and systematically evaluate the prevalence, 
timing, and clinical outcomes of unexpected requests for 
non-cardiac surgery or other invasive procedures during the 
first year after DES implantation. 
MATERIALS AND METHODS
　　　
Study population
The real safety and efficacy of 3-month DAPT following 
Endeavor zotarolimus-eluting stent (E-ZES; Medtronic, 
Inc., Santa Rosa, CA, USA) implantation trial (RESET tri-
al) was a prospective, open label, randomized trial conduct-
ed at 26 sites in Korea.8 The primary goal of this trial was 
to compare the safety and efficacy of two DES+DAPT im-
plantation strategies: E-ZES+3-month DAPT versus stan-
dard therapy (other DES+12-month DAPT). Details re-
garding study design, inclusion and exclusion criteria, and 
primary outcomes were provided in a prior publication.8 All 
participants were randomly assigned in a 1:1 ratio to re-
ceive either E-ZES+3-month DAPT (n=1059) or standard 
therapy (n=1058). After stent implantation, aspirin 100 mg 
daily was prescribed indefinitely; and the duration of treat-
ment with clopidogrel 75 mg daily was determined accord-
ing to the assigned randomized strategy. Clinical follow-up 
was performed at 1, 3, 6, and 12 months after the DES im-
plantation. In the RESET trial if possible at all, it was rec-
ommended that elective non-cardiac surgery or procedures 
with significant risk of bleeding were deferred until the 
completion of the appropriate DAPT, as recommended in 
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tients had more than one request to prematurely discontinue 
DAPT (Table 2). Among the 310 requests, 11.3% were <1 
month post-DES, 30.0% were between 1 and 3 months 
post-DES, 36.8% were between 4 and 6 months post-DES, 
and were 21.9% between 7 and 12 months post-DES im-
plantation. The types of procedures are also listed in Table 
2; only 6 (1.9%) were high-risk and 60 (19.4%) were inter-
mediate-risk. 
On the per-request level analysis, the rate of actual dis-
continuation of DAPT was 35.8% (111 of 310 requests). 
Only 53.2% (165 of 310 requests) procedures were actually 
performed. The remaining 145 (46.8%) procedures were 
postponed until >1 year after DES implantation. In 54 in-
stances, procedures were performed without discontinua-
tion of DAPT; no high-risk operation, 4 intermediate-risk, 
and 2 low-risk operation; 4 invasive diagnostic or therapeu-
tic procedures; 19 dental operation or procedures; and 25 
endoscopic operations or procedures. The types of proce-
dures finally performed are shown in Table 3. The rate of 
actual discontinuation of DAPT and the frequency of pro-
cedures actually performed according to follow-up inter-
vals from DES implantation are presented at Fig. 1. The 
rates of actual discontinuation of DAPT (p<0.001) and the 
rate of non-cardiac surgery or procedures finally performed 
(p=0.001) according to the timing of requests were signifi-
cantly different. 
On multivariate logistic regression analysis, the most sig-
nificant determinants for actual discontinuation of DAPT 
were E-ZES+3-month DAPT (odds ratio=5.54, 95% confi-
dence interval 2.95 to 10.44, p<0.001) and timing of request 
(odds ratio=2.84, 95% confidence interval 1.97 to 4.11, p< 
0.001) (Table 4).
Table 5 summarizes clinical outcomes. There were no 
deaths, myocardial infarctions, or stent thromboses related 
to actual discontinuation of DAPT in the setting of non-car-
diac surgery or other invasive procedures.
DISCUSSION
The main findings of this systematic and prospective analy-
sis were as follows: 1) there was a 14.6% rate of unexpect-
ed requests for discontinuation of DAPT because of unan-
ticipated need for non-cardiac surgery or other invasive 
procedures in 12.3% of patients during the first 12 months 
after DES implantation. 2) On a per-request level, proce-
dures were finally performed in about half of the requested 
hospital administration before operation or procedures were 
strongly recommended to monitor the patients’ subsequent 
symptoms or outcomes. The collection of questionaries was 
done by web-based report system (main way), mail, or tele-
phone-contact.
All analyses were performed on a per-patient and per-re-
quest level. In addition, we analyzed the occurrence of the 
primary endpoint of RESET trial, a composite of death from 
cardiovascular causes, myocardial infarction, stent throm-
bosis, target-vessel revascularization, or bleeding at 1 year 
post-procedure.8 Clinical events were defined according to 
the Academic Research Consortium as published previous-
ly.8-10 All requests, questionnaire data, and clinical events 
were independently monitored and assessed by a Clinical 
Event Committee. 
Statistical analysis
Statistical analyses were performed using the Statistical 
Analysis System software (SAS 9.1.3, SAS Institute, Cary, 
NC, USA). Categorical variables are expressed as numbers 
and percentages and compared using the chi-square test or 
Fisher’s exact test. Continuous variables are expressed as 
mean± standard deviation and compared with analysis of 
variance. Multivariate logistic regression analysis was per-
formed to assess the major determinants for actual discontin-
uation of DAPT. Univariate variables with p-value ≤0.05 and 
other expected factors influencing the actual discontinua-
tion of DAPT or risk factors for the occurrence of stent 
thrombosis (age, diabetes mellitus, hypertension, clinical 
presentations, types of non-cardiac surgery, stent diameter 
and length, and multi-vessel intervention or multiple stent-
ing) were entered into the final multivariate logistic regres-
sion model. p-values <0.05 were considered statistically 
significant.
 
RESULTS
 
A brief summary of baseline clinical and angiographic char-
acteristics in patients with or without unexpected requests 
for non-cardiac surgery or other invasive procedures is 
shown in Table 1. Of the patients requested for operation or 
invasive procedures (n=261), there was no patient with oral 
anticoagulant besides the antiplatelets such as aspirin or 
clopidogrel. Overall, there were 310 requests for non-cardi-
ac surgery or invasive procedures requiring premature dis-
continuation of DAPT in 261 patients (12.3%); 2.0% of pa-
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A first small study of 40 bare-metal stent-treated patients 
revealed an extraordinarily high incidence of catastrophic 
perioperative complications (34% mortality) in patients 
who underwent elective or semi-elective non-cardiac sur-
gery soon after stent implantation.11 In the DES era, the re-
ported risk associated with major non-cardiac surgery var-
ied widely from 0% to 22%, with most studies reporting a 
risk ≤6% in retrospective studies.12 In most studies, a longer 
time interval between DES implantation and non-cardiac 
cases (7.8%) with actual discontinuation of DAPT in ap-
proximately one-third of the requests. 3) Favorable clinical 
outcomes were observed in patients regardless of whether 
or not DAPT was discontinued or a procedure actually per-
formed. Because patients with planned non-cardiac surgery 
or invasive procedures were excluded from the RESET trial 
before randomization, these requests for non-cardiac sur-
gery and invasive procedures after DES implantation in this 
study were completely unexpected. 
Table 1. Baseline Clinical and Angiographic Characteristics
Variables
Requests for non-cardiac surgery or 
other procedures No requests
(n=1856)
p value
Actual discontinuation 
of DAPT (n=93)
No discontinuation 
of DAPT (n=168)
Clinical characteristics
    Age, yrs 64.4±8.6 61.9±9.0 62.3±9.7 0.101
    Male sex, n (%) 60 (64.5) 112 (66.7) 1175 (63.3) 0.676
    Hypertension, n (%) 56 (60.2)   97 (57.7) 1157 (62.3) 0.473
    Diabetes mellitus, n (%) 22 (23.7)   41 (24.4)   558 (30.1) 0.143
    Dyslipidemia, n (%) 54 (58.1)   99 (58.9) 1092 (58.8) 0.989
    Current smoker, n (%) 16 (17.2)   35 (20.8)   457 (24.6) 0.159
    Acute myocardial infarction, n (%) 10 (10.8) 16 (9.5)   276 (14.9) 0.101
Angiographic and procedural characteristics
    No. of lesions, n 114 224 2349
    Lesion length, mm   19.5±10.3   18.6±10.4   20.0±10.4 0.171
    Type of drug-eluting stent, n (%) <0.001
        Endeavor zotarolimus-eluting stents 78 (68.4)   92 (41.1) 1171 (49.9)
        Cypher sirolimus-eluting stents 13 (11.4)   63 (28.1)   307 (13.1)
        Xience everolimus-eluting stents 6 (5.3)   41 (18.3)   357 (15.2)
        Resolute zotarolimus-eluting stents 17 (14.9)   28 (12.5)   514 (21.9)
    Multi-vessel intervention per patient, n (%) 22 (23.7)   39 (23.2)   420 (22.6) 0.962
    Stent diameter, mm   3.17±0.41   3.15±0.38   3.18±0.69 0.844
    Stent length per lesion, mm 21.9±7.1 21.0±8.5   22.9±10.0 0.147
    Pre-procedural minimum luminal diameter, mm   1.1±0.5   1.0±0.5   1.0±0.5 0.328
    Post-procedural minimum luminal diameter, mm   2.8±0.4   2.7±0.4   2.7±0.4 0.670
    Timing of the first request*, n (%) <0.001
        <1 month 3 (3.2)   32 (19.0) -
        1-3 months 20 (21.5)   60 (35.7) -
        4-6 months 42 (45.2)   54 (32.1) -
        7-12 months 28 (30.1)   22 (13.1) -
    Types of non-cardiac surgery or procedures 
      proposed in the first request*, n (%)
0.006
        High-risk operation 4 (4.3)   1 (0.6) -
        Intermediate-risk operation 28 (30.1)   26 (15.5) -
        Low-risk operation 3 (3.2) 15 (8.9) -
        Invasive procedures 4 (4.3) 10 (6.0) -
        Dental operation or procedures 23 (24.7)   62 (36.9) -
        Endoscopic operation or procedures 31 (33.3)   54 (32.1) -
DAPT, dual antiplatelet therapy.
*The first request was the first among multiple requests in patients in whom there were two or more requests to discontinue DAPT.
Non-Cardiac Surgery after DES
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DAPT was discontinued and surgery or an invasive proce-
dure actually performed. However, this is a prospective, ran-
domized study in which patients with planned procedures 
were completely excluded before randomization. Second, 
E-ZES was used in half of study participants; sufficient 
stent strut neointimal coverage in the early stage following 
E-ZES implantation might have played a protective role 
surgery was found to be associated with a lower risk of peri-
operative complications.12-14 Accordingly, the current Amer-
ican College of Cardiology/American Heart Association 
guidelines recommended delaying non-cardiac surgery for 
12 months after implantation of DES.6,7,12
Compared to the previous studies,11,12 the current study 
showed favorable clinical outcomes even in patients in whom 
Table 2. Unexpected Requests for Discontinuation of Dual 
Antiplatelet Therapy due to Non-Cardiac Surgery or Other 
Invasive Procedures
Total (n=2117)
Per-patient level
    No. of patients receiving requests to 
      discontinue DAPT, n (%)
261 (12.3)
    No. of requests, n (%) 
        1 219 (10.3)
        ≥2   42 (2.0)
    Timing of the first request*, n (%)
        <1 month   35 (13.4)
        1-3 months   80 (30.7)
        4-6 months   96 (36.8)
        7-12 months   50 (19.2)
Per-request level
    No. of requests to discontinue DAPT, 
      n (%)
310 (14.6)
    Types of non-cardiac surgery or 
      procedures proposed, n (%)
        High-risk operation     6 (1.9)
            Emergency operation     6
        Intermediate-risk operation   60 (19.4)
            Intraperitoneal operation   19 (31.7)
            Intrathoracic operation     2 (3.3)
            Head and neck surgery     9 (15.0)
            Orthopedic surgery   19 (31.7)
            Prostate surgery   11 (18.3)
        Low-risk operation   23 (7.4)
            Cataract surgery   18 (78.3)
            Ambulatory surgery     5 (21.7)
        Invasive procedures   14 (4.5)
        Dental operation or procedures 102 (32.9)
        Endoscopic operation or procedures 105 (33.9)
            Gastroscopy procedures   58 (55.2)
            Colonoscopy procedures   47 (44.8)
    Timing of the requests
         <1 month   35 (11.3)
        1-3 months   93 (30.0)
        4-6 months 114 (36.8)
        7-12 months   68 (21.9)
DAPT, dual antiplatelet therapy.
*The first request was the first among multiple requests in patients in 
whom there were two or more requests to discontinue DAPT.
Table 3. Types of Non-Cardiac Surgery or Other Invasive 
Procedures Finally Performed and the Actual Use of Dual 
Antiplatelet Therapy during Non-Cardiac Surgery or Other 
Invasive Procedures
Total request 
(n=310)
Total No. of non-cardiac surgery or 
  procedures finally performed
165
Types of non-cardiac surgery or procedures 
  finally performed, n (%)
    High-risk operation     5 (3.0)
    Intermediate-risk operation   37 (22.4)
    Low-risk operation     5 (3.0)
    Invasive procedures     8 (4.8)
    Dental operation or procedures   45 (27.3)
    Endoscopic operation or procedures   65 (39.4)
Use of DAPT
    Cases with actual discontinuation of DAPT, 
      n (%)
111 (67.3)
        Non-antiplatelet therapy   97 (87.4)
         Aspirin monotherapy   14 (12.6)
    Cases maintaining DAPT, n (%)   54 (32.7)
DAPT, dual antiplatelet therapy.
Fig. 1. Rate of actual discontinuation of dual antiplatelet therapy (DAPT) 
and non-cardiac surgery or other invasive procedures finally performed on 
patients with requests according to the follow-up intervals from DES im-
plantation. The numbers outside the boxes represent the rates of actual 
discontinuation of DAPT and surgery or procedures finally performed. DES, 
drug-eluting stent.
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underwent non-cardiac surgery or other invasive procedures.  
A recent retrospective registry of 4637 patients showed 
that the incidence of major non-cardiac surgery was 4.4% 
within 1 year after DES implantation, and that the risk of 
composite outcome of cardiac death, myocardial infarction, 
or stent thrombosis increased 27-fold in the week following 
non-cardiac surgery compared with any other week after 
stent implantation.19 Data from the same registry revealed 
that minor surgery was performed in 2.0% of 8323 DES-
treated patients.12 Another systematic analysis revealed that 
26% of 11151 patients who underwent percutaneous coro-
nary intervention also underwent at least 1 non-cardiac sur-
gery during the 5 years after index procedures; 23% ortho-
pedic, 20% abdominal, 12% urologic, 10% vascular, and 
35% others.20 However, the procedures in this study were 
high-risk operation in 3.0%, intermediate-risk operation in 
22.4%, low-risk operation in 3.0%, invasive procedures and 
non-surgical in 4.8%, dental surgery or procedures in 27.3%, 
and endoscopic surgery or procedures in 39.4%. 
In the current study, there were 310 unanticipated requests 
(14.6%) and 165 procedures (7.8%) actually performed. 
Thus, the need for non-cardiac surgery and invasive proce-
dures normally associated with premature discontinuation of 
DAPT could be more frequent than expected after DES im-
plantation. Individual patient risk stratification should be 
assessed before DES implantation, especially in older pa-
tients.20 For each 10-year increase in age, there was a 1.3-
fold increase in the incidence of non-cardiac surgery (p< 
against the occurrence of stent thrombosis in the situation 
of actual discontinuation of DAPT.8.15,16 Third, second-gen-
eration DESs - that have more favorable clinical outcomes, 
drug-release kinetics, and polymer characteristics than first-
generation DES17,18 - were also frequently used in the stan-
dard therapy group. Fourth, the number of patients receiving 
the requests of DAPT discontinuation was small. Especially, 
the rate of high-risk operation out of all non-cardiac surgery 
or procedures proposed was low in this study. All these fac-
tors might have contributed to the favorable clinical out-
comes in patients with actual discontinuation of DAPT who 
Table 5. Clinical Outcomes 
Total
No. of patients receiving the requests to 
  discontinue DAPT, n
261
    Clinical outcomes during follow-up, n (%)
        Death 0 (0.0)
        Myocardial infarction 0 (0.0)
        Stent thrombosis 0 (0.0)
        Target-vessel revascularization 6 (2.3)
        Bleeding
            Major or minor 4 (1.5)
            Major 3 (1.1)
    Cerebrovascular accidents 2 (0.8)
No. of patients with actual discontinuation of 
  DAPT, n (%)
93 (35.6)
     Any death, myocardial infarction, or stent 
      thrombosis 
0 (0.0)
DAPT, dual antiplatelet therapy.
Table 4. Univariate and Multivariate Analyses for Determinants of Actual Discontinuation of Dual Antiplatelet Therapy
Variables
Univariate Multivariate
Odds 
ratio
95% confidential 
interval
p value
Odds 
ratio
95% confidential 
interval
p value
Clinical variables
    Age ≥60 yrs 1.47 0.87-2.49 0.152 1.40 0.73-2.70 0.317
    Male sex 0.94 0.55-1.58 0.803 0.72 0.37-1.40 0.336
    Diabetes mellitus 0.87 0.49-1.59 0.672 0.78 0.39-1.58 0.489
    Hypertension 0.92 0.56-1.54 0.771 0.87 0.46-1.62 0.659
    Acute myocardial infarction 0.91 0.43-2.19 0.838 0.88 0.33-2.38 0.802
    Multi-vessel diseases 1.36 0.82-2.26 0.232 1.89 0.89-4.04 0.100
    Types of operations or procedures 0.92 0.71-1.19 0.506 0.84 0.62-1.14 0.269
    Timing of request, as increased per 3 months 3.20 1.98-4.07 <0.001 2.84 1.97-4.11 <0.001
Angiographic and procedural variables
    E-ZES+3-month DAPT 5.04 2.36-8.40 <0.001 5.54   2.95-10.44 <0.001
    Multi-vessel intervention 0.93 0.39-2.45 0.723 0.94 0.38-2.33 0.897
    No. of stents implanted ≥2 0.70 0.31-1.36 0.192 0.61 0.28-1.33 0.215
    Stent diameter ≤2.75 mm 1.20 0.64-2.30 0.568 1.09 0.52-2.27 0.824
    Stent length ≥20 mm 1.92 0.89-3.83 0.097 1.84 0.87-3.87 0.110
E-ZES, endeavor zotarolimus-eluting stents; DAPT, dual antiplatelet therapy.
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cardiography, American Society of Nuclear Cardiology, Heart 
Rhythm Society, Society of Cardiovascular Anesthesiologists, So-
ciety for Cardiovascular Angiography and Interventions, Society 
for Vascular Medicine and Biology, and Society for Vascular Sur-
gery. Circulation 2007;116:1971-96. 
8. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A 
new strategy for discontinuation of dual antiplatelet therapy: the 
RESET Trial (REal Safety and Efficacy of 3-month dual antiplate-
let Therapy following Endeavor zotarolimus-eluting stent implan-
tation). J Am Coll Cardiol 2012;60:1340-8. 
9. Task Force for Preoperative Cardiac Risk Assessment and Periop-
erative Cardiac Management in Non-cardiac Surgery; European 
Society of Cardiology (ESC), Poldermans D, Bax JJ, Boersma E, 
De Hert S, et al. Guidelines for pre-operative cardiac risk assess-
ment and perioperative cardiac management in non-cardiac sur-
gery. Eur Heart J 2009;30:2769-812. 
10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es 
GA, et al. Clinical end points in coronary stent trials: a case for 
standardized definitions. Circulation 2007;115:2344-51.
11. Kałuza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Cata-
strophic outcomes of noncardiac surgery soon after coronary 
stenting. J Am Coll Cardiol 2000;35:1288-94.
0.0001) (about 15% in ages <50 years and more than 30% 
in ages >70 years).20
This study has limitations. First, the analysis was per-
formed using random study data with specific inclusion and 
exclusion criteria and close patient follow-up typical of a 
randomized trial. Therefore, the results of this study may 
not apply to patients with clinically unstable presentation 
and angiographically more complex lesion subsets that are 
treated in real-world settings. In addition, because the pa-
tients with planned procedures were completely excluded 
in this study, the clinical outcomes of this subset could not 
be known from RESET study. Second, because the number 
of patients with actual DAPT discontinuation was small, a 
long-term data with a large population are needed. Finally, 
although the analyses on the detailed reasons for postpon-
ing or actually performing operation or procedures irre-
spective of the discontinuation of DAPT are important for 
the understanding of the general management of the pa-
tients with DES, we could not perform these analyses be-
cause of lack of data regarding the reasons for the final phy-
sicians’ decisions.  
In conclusion, the requests for unexpected non-cardiac 
surgery or other invasive procedure typically requiring pre-
mature discontinuation of DAPT could be more frequent 
than expected. However, approximately half of these proce-
dures were not performed at the time of request. Neverthe-
less, actual discontinuation of DAPT and non-cardiac sur-
gery or other invasive procedures did not contribute to an 
increased risk of adverse cardiovascular events including 
death, myocardial infarction, or stent thrombosis in the pa-
tients enrolled in the RESET trial.  
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